Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Stoke Therapeutics Inc.

    NASDAQ: STOK · Real-Time Price · USD
    11.67
    -0.03 (-0.26%)
    At close: Jun 17, 2025, 3:59 PM
    11.66
    -0.09%
    After-hours: Jun 17, 2025, 04:04 PM EDT
    -0.26%
    Bid 11.62
    Market Cap 637.15M
    Revenue (ttm) 190.91M
    Net Income (ttm) 50.27M
    EPS (ttm) 0.82
    PE Ratio (ttm) 14.23
    Forward PE -4.21
    Analyst Buy
    Ask 12
    Volume 480,198
    Avg. Volume (20D) 811,909
    Open 11.70
    Previous Close 11.70
    Day's Range 11.50 - 11.95
    52-Week Range 5.35 - 16.15
    Beta 1.10

    About STOK

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol STOK
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for STOK stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    6 months ago
    +12.07%
    Stoke Therapeutics shares are trading higher after... Unlock content with Pro Subscription
    7 months ago
    +1.53%
    Stoke Therapeutics shares are trading higher on possible continued strength following Q3 reported financial results yesterday. Also, Needham and HC Wainwright & Co. reiterated Buy ratings on the stock.
    news image

    1 day ago · businesswire.com

    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...

    news image

    3 days ago · seekingalpha.com

    Stoke Therapeutics: Impressive Pipeline And Big Backers

    Stoke Therapeutics is pioneering RNA-based therapies, with a lead candidate for Dravet Syndrome aiming for true disease modification, unlike current symptom-focused treatments. The company's pipeline ...

    news image

    2 weeks ago · businesswire.com

    Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

    BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...

    news image

    1 month ago · zacks.com

    Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet

    The consensus price target hints at a 132.4% upside potential for Stoke Therapeutics (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin...

    news image

    1 month ago · zacks.com

    Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates

    Stoke Therapeutics, Inc. (STOK) came out with quarterly earnings of $1.90 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.57 per share a year ...

    news image

    1 month ago · businesswire.com

    Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

    BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...

    news image

    1 month ago · zacks.com

    Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

    Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    1 month ago · zacks.com

    Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock?

    Stoke Therapeutics (STOK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    news image

    1 month ago · zacks.com

    Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock?

    Stoke Therapeutics (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength d...

    news image

    2 months ago · businesswire.com

    Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

    BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...

    Add to Watchlist